Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone, GHRH(1-44). Ferdinandi et al. studied the analog TH9507 in pigs, rats, and dogs and reported increased circulating growth hormone (GH) and IGF-1. Those endocrine measurements do not establish preserved physiological feedback.
Secretagogue Mechanism
The cited TH9507 abstract reports GH and IGF-1 measurements in pigs, rats, and dogs, rather than a direct GHRH-receptor binding assay. It attributes adverse findings in dogs to prolonged supraphysiological GH and/or IGF-1 exposure; this does not demonstrate normal feedback regulation.
Structural Stabilization
Native GHRH is rapidly degraded, primarily by dipeptidyl peptidase-4 (DPP-4). Tesamorelin carries an N-terminal trans-3-hexenoyl modification that confers resistance to this degradation, extending its stability relative to native GHRH. It is a common reference compound in structure-stability studies of GHRH-family peptides.
Research Applications
- GH/IGF-1 measurements in pig, rat, and dog models
- Comparative secretagogue studies (GHRH analogs vs ghrelin-receptor agonists)
- DPP-4 resistance and peptide-stabilization research
- Bone and connective-tissue repair models within the GH axis
References
- Ferdinandi ES, Brazeau P, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol 2007. PMID: 17214611.
- Frohman LA, Downs TR, Heimer EP, et al. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 1989. PMID: 2565342.
This article summarizes publicly available research for educational purposes and does not constitute medical advice, a therapeutic claim, or a recommendation for human use. Products referenced are sold for laboratory research use only.